Dabigatran Etexilate Is Cost Effective for Stroke Prevention in Atrial Fibrillation in Real-World Clinical Practice
A new economic analysis, published online in Thrombosis
and Haemostasis, suggested that Boehringer Ingelheim's novel oral direct
thrombin inhibitor dabigatran etexilate is cost-effective compared to current
treatment options, particularly in real-world clinical practice.1,2
National Stroke Association’s mission is to reduce the incidence and impact of stroke by developing compelling education and programs focused on prevention, treatment, rehabilitation and support for all impacted by stroke.